DK175500B1 - Sammensætning til beskyttelse af et dyr eller et menneske mod en infektion fremkaldt af et respiratorisk syncytialt virus samt underenhedsvaccineformulering - Google Patents

Sammensætning til beskyttelse af et dyr eller et menneske mod en infektion fremkaldt af et respiratorisk syncytialt virus samt underenhedsvaccineformulering Download PDF

Info

Publication number: DK175500B1
Authority: DK; Denmark
Prior art keywords: virus; protein; animals; fusion protein; group
Prior art date: 1987-09-29

Application number

DK199000791A

Other languages

Danish (da)

English (en)

Other versions

DK79190D0 (da

DK79190A (da

Inventor

Peter R Paradiso

Stephen W Hildreth

Branda T Hu

Antonia Martin-Gallardo

Rasappa Arumugham

Original Assignee

Wyeth Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1987-09-29

Filing date

1990-03-28

Publication date

2004-11-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26799096&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK175500(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1990-03-28 Application filed by Wyeth Corp filed Critical Wyeth Corp

1990-03-28 Publication of DK79190D0 publication Critical patent/DK79190D0/da

1990-05-07 Publication of DK79190A publication Critical patent/DK79190A/da

2004-11-15 Application granted granted Critical

2004-11-15 Publication of DK175500B1 publication Critical patent/DK175500B1/da

Links

239000000203 mixture Substances 0.000 title claims abstract description 33
241000725643 Respiratory syncytial virus Species 0.000 title claims abstract description 8
241001465754 Metazoa Species 0.000 title claims description 97
208000015181 infectious disease Diseases 0.000 title claims description 46
241000282414 Homo sapiens Species 0.000 title claims description 32
238000009472 formulation Methods 0.000 title claims description 23
229940031626 subunit vaccine Drugs 0.000 title claims description 10
108091006027 G proteins Proteins 0.000 claims abstract description 64
108091000058 GTP-Binding Proteins 0.000 claims abstract description 64
102000030782 GTP binding Human genes 0.000 claims abstract description 60
108010059722 Viral Fusion Proteins Proteins 0.000 claims abstract description 53
229960005486 vaccine Drugs 0.000 claims abstract description 39
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 35
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 34
229920001184 polypeptide Polymers 0.000 claims abstract description 31
230000003472 neutralizing effect Effects 0.000 claims abstract description 26
230000002163 immunogen Effects 0.000 claims description 34
239000002671 adjuvant Substances 0.000 claims description 11
239000003937 drug carrier Substances 0.000 claims 2
230000004927 fusion Effects 0.000 abstract description 27
239000002773 nucleotide Substances 0.000 abstract description 11
125000003729 nucleotide group Chemical group 0.000 abstract description 11
241000711920 Human orthopneumovirus Species 0.000 abstract 1
241000700605 Viruses Species 0.000 description 233
108090000623 proteins and genes Proteins 0.000 description 139
235000018102 proteins Nutrition 0.000 description 85
102000004169 proteins and genes Human genes 0.000 description 85
210000004027 cell Anatomy 0.000 description 66
230000003053 immunization Effects 0.000 description 48
238000002649 immunization Methods 0.000 description 46
108020001507 fusion proteins Proteins 0.000 description 44
108010068327 4-hydroxyphenylpyruvate dioxygenase Proteins 0.000 description 43
210000004072 lung Anatomy 0.000 description 42
102000037865 fusion proteins Human genes 0.000 description 40
238000012360 testing method Methods 0.000 description 40
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 36
239000002953 phosphate buffered saline Substances 0.000 description 36
238000000034 method Methods 0.000 description 31
230000014509 gene expression Effects 0.000 description 30
210000001519 tissue Anatomy 0.000 description 28
210000002966 serum Anatomy 0.000 description 27
239000013598 vector Substances 0.000 description 27
108020004414 DNA Proteins 0.000 description 23
239000013604 expression vector Substances 0.000 description 23
239000013612 plasmid Substances 0.000 description 21
241000144282 Sigmodon Species 0.000 description 19
229940037003 alum Drugs 0.000 description 19
239000012634 fragment Substances 0.000 description 18
239000000523 sample Substances 0.000 description 17
230000001681 protective effect Effects 0.000 description 16
230000009385 viral infection Effects 0.000 description 15
201000010099 disease Diseases 0.000 description 14
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
241000283973 Oryctolagus cuniculus Species 0.000 description 13
108020004511 Recombinant DNA Proteins 0.000 description 13
230000000694 effects Effects 0.000 description 13
230000005847 immunogenicity Effects 0.000 description 13
238000002347 injection Methods 0.000 description 13
239000007924 injection Substances 0.000 description 13
238000004519 manufacturing process Methods 0.000 description 13
241000588724 Escherichia coli Species 0.000 description 12
108091028043 Nucleic acid sequence Proteins 0.000 description 11
241000700618 Vaccinia virus Species 0.000 description 11
230000003141 anti-fusion Effects 0.000 description 11
238000003780 insertion Methods 0.000 description 11
230000037431 insertion Effects 0.000 description 11
230000014616 translation Effects 0.000 description 11
241000894006 Bacteria Species 0.000 description 10
241000711895 Bovine orthopneumovirus Species 0.000 description 10
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 10
241000282520 Papio Species 0.000 description 10
239000007927 intramuscular injection Substances 0.000 description 10
238000010255 intramuscular injection Methods 0.000 description 10
238000013519 translation Methods 0.000 description 10
241000701447 unidentified baculovirus Species 0.000 description 10
241000283690 Bos taurus Species 0.000 description 9
230000002829 reductive effect Effects 0.000 description 9
239000000243 solution Substances 0.000 description 9
230000003612 virological effect Effects 0.000 description 9
WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 8
230000027455 binding Effects 0.000 description 8
238000013518 transcription Methods 0.000 description 8
230000035897 transcription Effects 0.000 description 8
230000010530 Virus Neutralization Effects 0.000 description 7
235000001014 amino acid Nutrition 0.000 description 7
238000010171 animal model Methods 0.000 description 7
238000006243 chemical reaction Methods 0.000 description 7
238000010790 dilution Methods 0.000 description 7
239000012895 dilution Substances 0.000 description 7
238000002474 experimental method Methods 0.000 description 7
230000006870 function Effects 0.000 description 7
230000028993 immune response Effects 0.000 description 7
238000006386 neutralization reaction Methods 0.000 description 7
238000002360 preparation method Methods 0.000 description 7
102100034613 Annexin A2 Human genes 0.000 description 6
102000053602 DNA Human genes 0.000 description 6
150000001413 amino acids Chemical class 0.000 description 6
239000000427 antigen Substances 0.000 description 6
102000036639 antigens Human genes 0.000 description 6
108091007433 antigens Proteins 0.000 description 6
230000001580 bacterial effect Effects 0.000 description 6
230000015572 biosynthetic process Effects 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
238000010367 cloning Methods 0.000 description 6
210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
229910003460 diamond Inorganic materials 0.000 description 6
239000010432 diamond Substances 0.000 description 6
238000001962 electrophoresis Methods 0.000 description 6
239000000499 gel Substances 0.000 description 6
230000001900 immune effect Effects 0.000 description 6
239000002609 medium Substances 0.000 description 6
108020004999 messenger RNA Proteins 0.000 description 6
210000000952 spleen Anatomy 0.000 description 6
238000012546 transfer Methods 0.000 description 6
241000701161 unidentified adenovirus Species 0.000 description 6
238000002255 vaccination Methods 0.000 description 6
241000283707 Capra Species 0.000 description 5
238000002965 ELISA Methods 0.000 description 5
102000004190 Enzymes Human genes 0.000 description 5
108090000790 Enzymes Proteins 0.000 description 5
108090000288 Glycoproteins Proteins 0.000 description 5
102000003886 Glycoproteins Human genes 0.000 description 5
241000238631 Hexapoda Species 0.000 description 5
241000282412 Homo Species 0.000 description 5
241000699670 Mus sp. Species 0.000 description 5
239000000539 dimer Substances 0.000 description 5
239000001963 growth medium Substances 0.000 description 5
230000036039 immunity Effects 0.000 description 5
238000000338 in vitro Methods 0.000 description 5
210000004962 mammalian cell Anatomy 0.000 description 5
239000000546 pharmaceutical excipient Substances 0.000 description 5
238000003259 recombinant expression Methods 0.000 description 5
239000000758 substrate Substances 0.000 description 5
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
240000004808 Saccharomyces cerevisiae Species 0.000 description 4
239000002253 acid Substances 0.000 description 4
238000013459 approach Methods 0.000 description 4
230000002238 attenuated effect Effects 0.000 description 4
238000004113 cell culture Methods 0.000 description 4
238000003776 cleavage reaction Methods 0.000 description 4
IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 4
238000003018 immunoassay Methods 0.000 description 4
238000007918 intramuscular administration Methods 0.000 description 4
238000002955 isolation Methods 0.000 description 4
230000036285 pathological change Effects 0.000 description 4
231100000915 pathological change Toxicity 0.000 description 4
230000007170 pathology Effects 0.000 description 4
230000002685 pulmonary effect Effects 0.000 description 4
230000006798 recombination Effects 0.000 description 4
230000007017 scission Effects 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
230000002103 transcriptional effect Effects 0.000 description 4
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
108090000668 Annexin A2 Proteins 0.000 description 3
AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
108091081024 Start codon Proteins 0.000 description 3
206010046865 Vaccinia virus infection Diseases 0.000 description 3
125000003275 alpha amino acid group Chemical group 0.000 description 3
230000000890 antigenic effect Effects 0.000 description 3
238000003556 assay Methods 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
239000002299 complementary DNA Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
238000007598 dipping method Methods 0.000 description 3
230000002068 genetic effect Effects 0.000 description 3
230000012010 growth Effects 0.000 description 3
108700023453 human respiratory syncytial virus F Proteins 0.000 description 3
230000002458 infectious effect Effects 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
230000000977 initiatory effect Effects 0.000 description 3
238000001990 intravenous administration Methods 0.000 description 3
238000002372 labelling Methods 0.000 description 3
150000002632 lipids Chemical class 0.000 description 3
239000007788 liquid Substances 0.000 description 3
VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
239000013642 negative control Substances 0.000 description 3
239000002245 particle Substances 0.000 description 3
230000037361 pathway Effects 0.000 description 3
239000013600 plasmid vector Substances 0.000 description 3
238000012545 processing Methods 0.000 description 3
238000005215 recombination Methods 0.000 description 3
230000010076 replication Effects 0.000 description 3
229910052709 silver Inorganic materials 0.000 description 3
239000004332 silver Substances 0.000 description 3
238000001890 transfection Methods 0.000 description 3
230000009466 transformation Effects 0.000 description 3
208000007089 vaccinia Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 3
TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 2
LVSPDZAGCBEQAV-UHFFFAOYSA-N 4-chloronaphthalen-1-ol Chemical compound C1=CC=C2C(O)=CC=C(Cl)C2=C1 LVSPDZAGCBEQAV-UHFFFAOYSA-N 0.000 description 2
206010067484 Adverse reaction Diseases 0.000 description 2
102100036850 C-C motif chemokine 23 Human genes 0.000 description 2
108020004705 Codon Proteins 0.000 description 2
WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
238000007900 DNA-DNA hybridization Methods 0.000 description 2
102000004163 DNA-directed RNA polymerases Human genes 0.000 description 2
101000713081 Homo sapiens C-C motif chemokine 23 Proteins 0.000 description 2
108010001336 Horseradish Peroxidase Proteins 0.000 description 2
235000021360 Myristic acid Nutrition 0.000 description 2
TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 2
108091034117 Oligonucleotide Proteins 0.000 description 2
235000021314 Palmitic acid Nutrition 0.000 description 2
241000364057 Peoria Species 0.000 description 2
101710182846 Polyhedrin Proteins 0.000 description 2
241000700159 Rattus Species 0.000 description 2
102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical group O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
210000001744 T-lymphocyte Anatomy 0.000 description 2
108020004440 Thymidine kinase Proteins 0.000 description 2
108010067390 Viral Proteins Proteins 0.000 description 2
230000006838 adverse reaction Effects 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
239000013602 bacteriophage vector Substances 0.000 description 2
230000006399 behavior Effects 0.000 description 2
239000000872 buffer Substances 0.000 description 2
150000001720 carbohydrates Chemical class 0.000 description 2
235000014633 carbohydrates Nutrition 0.000 description 2
239000011545 carbonate/bicarbonate buffer Substances 0.000 description 2
230000007910 cell fusion Effects 0.000 description 2
239000003153 chemical reaction reagent Substances 0.000 description 2
210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
210000000349 chromosome Anatomy 0.000 description 2
239000004927 clay Substances 0.000 description 2
238000010276 construction Methods 0.000 description 2
230000006378 damage Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
238000010586 diagram Methods 0.000 description 2
235000014113 dietary fatty acids Nutrition 0.000 description 2
241001493065 dsRNA viruses Species 0.000 description 2
239000012636 effector Substances 0.000 description 2
238000005516 engineering process Methods 0.000 description 2
230000002255 enzymatic effect Effects 0.000 description 2
238000006911 enzymatic reaction Methods 0.000 description 2
210000000416 exudates and transudate Anatomy 0.000 description 2
229930195729 fatty acid Natural products 0.000 description 2
239000000194 fatty acid Substances 0.000 description 2
150000004665 fatty acids Chemical class 0.000 description 2
239000000834 fixative Substances 0.000 description 2
238000010438 heat treatment Methods 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
238000012744 immunostaining Methods 0.000 description 2
238000001727 in vivo Methods 0.000 description 2
230000002779 inactivation Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000030500 lower respiratory tract disease Diseases 0.000 description 2
239000000463 material Substances 0.000 description 2
239000011159 matrix material Substances 0.000 description 2
230000001404 mediated effect Effects 0.000 description 2
239000012528 membrane Substances 0.000 description 2
244000005700 microbiome Species 0.000 description 2
235000013336 milk Nutrition 0.000 description 2
239000008267 milk Substances 0.000 description 2
210000004080 milk Anatomy 0.000 description 2
230000004048 modification Effects 0.000 description 2
238000012986 modification Methods 0.000 description 2
229940031348 multivalent vaccine Drugs 0.000 description 2
WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
108020004707 nucleic acids Proteins 0.000 description 2
102000039446 nucleic acids Human genes 0.000 description 2
150000007523 nucleic acids Chemical class 0.000 description 2
230000001575 pathological effect Effects 0.000 description 2
102000013415 peroxidase activity proteins Human genes 0.000 description 2
108040007629 peroxidase activity proteins Proteins 0.000 description 2
108091033319 polynucleotide Proteins 0.000 description 2
102000040430 polynucleotide Human genes 0.000 description 2
239000002157 polynucleotide Substances 0.000 description 2
239000013641 positive control Substances 0.000 description 2
239000000843 powder Substances 0.000 description 2
230000002265 prevention Effects 0.000 description 2
230000008569 process Effects 0.000 description 2
230000000644 propagated effect Effects 0.000 description 2
235000004252 protein component Nutrition 0.000 description 2
229940023143 protein vaccine Drugs 0.000 description 2
230000002797 proteolythic effect Effects 0.000 description 2
238000000746 purification Methods 0.000 description 2
238000003156 radioimmunoprecipitation Methods 0.000 description 2
230000009257 reactivity Effects 0.000 description 2
230000009467 reduction Effects 0.000 description 2
230000001105 regulatory effect Effects 0.000 description 2
230000000241 respiratory effect Effects 0.000 description 2
208000023504 respiratory system disease Diseases 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
238000010561 standard procedure Methods 0.000 description 2
238000007920 subcutaneous administration Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
208000024891 symptom Diseases 0.000 description 2
238000003786 synthesis reaction Methods 0.000 description 2
238000011282 treatment Methods 0.000 description 2
230000001960 triggered effect Effects 0.000 description 2
241001515965 unidentified phage Species 0.000 description 2
210000003501 vero cell Anatomy 0.000 description 2
DIGQNXIGRZPYDK-WKSCXVIASA-N (2R)-6-amino-2-[[2-[[(2S)-2-[[2-[[(2R)-2-[[(2S)-2-[[(2R,3S)-2-[[2-[[(2S)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2S,3S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[2-[[(2S)-2-[[(2R)-2-[[2-[[2-[[2-[(2-amino-1-hydroxyethylidene)amino]-3-carboxy-1-hydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxypropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1,5-dihydroxy-5-iminopentylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxybutylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1,3-dihydroxypropylidene]amino]-1-hydroxyethylidene]amino]-1-hydroxy-3-sulfanylpropylidene]amino]-1-hydroxyethylidene]amino]hexanoic acid Chemical compound C[C@@H]([C@@H](C(=N[C@@H](CS)C(=N[C@@H](C)C(=N[C@@H](CO)C(=NCC(=N[C@@H](CCC(=N)O)C(=NC(CS)C(=N[C@H]([C@H](C)O)C(=N[C@H](CS)C(=N[C@H](CO)C(=NCC(=N[C@H](CS)C(=NCC(=N[C@H](CCCCN)C(=O)O)O)O)O)O)O)O)O)O)O)O)O)O)O)N=C([C@H](CS)N=C([C@H](CO)N=C([C@H](CO)N=C([C@H](C)N=C(CN=C([C@H](CO)N=C([C@H](CS)N=C(CN=C(C(CS)N=C(C(CC(=O)O)N=C(CN)O)O)O)O)O)O)O)O)O)O)O)O DIGQNXIGRZPYDK-WKSCXVIASA-N 0.000 description 1
BHMLFPOTZYRDKA-IRXDYDNUSA-N (2s)-2-[(s)-(2-iodophenoxy)-phenylmethyl]morpholine Chemical compound IC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 BHMLFPOTZYRDKA-IRXDYDNUSA-N 0.000 description 1
ASWBNKHCZGQVJV-UHFFFAOYSA-N (3-hexadecanoyloxy-2-hydroxypropyl) 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCCCCCCCCCC(=O)OCC(O)COP([O-])(=O)OCC[N+](C)(C)C ASWBNKHCZGQVJV-UHFFFAOYSA-N 0.000 description 1
FJLUATLTXUNBOT-UHFFFAOYSA-N 1-Hexadecylamine Chemical compound CCCCCCCCCCCCCCCCN FJLUATLTXUNBOT-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 1
IPCSVZSSVZVIGE-PTGCLLIWSA-N 9,10-ditritiohexadecanoic acid Chemical compound CCCCCCC([3H])C([3H])CCCCCCCC(O)=O IPCSVZSSVZVIGE-PTGCLLIWSA-N 0.000 description 1
108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
101100515517 Arabidopsis thaliana XI-I gene Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
206010006448 Bronchiolitis Diseases 0.000 description 1
101100191768 Caenorhabditis elegans pbs-4 gene Proteins 0.000 description 1
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
108091026890 Coding region Proteins 0.000 description 1
SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
102000004594 DNA Polymerase I Human genes 0.000 description 1
108010017826 DNA Polymerase I Proteins 0.000 description 1
108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
MHZGKXUYDGKKIU-UHFFFAOYSA-N Decylamine Chemical compound CCCCCCCCCCN MHZGKXUYDGKKIU-UHFFFAOYSA-N 0.000 description 1
240000006497 Dianthus caryophyllus Species 0.000 description 1
235000009355 Dianthus caryophyllus Nutrition 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
241000305071 Enterobacterales Species 0.000 description 1
241000208421 Ericaceae Species 0.000 description 1
101001090612 Escherichia phage Mu Protease I Proteins 0.000 description 1
241000206602 Eukaryota Species 0.000 description 1
PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 description 1
101710160621 Fusion glycoprotein F0 Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
108020005350 Initiator Codon Proteins 0.000 description 1
SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
241000272168 Laridae Species 0.000 description 1
206010025323 Lymphomas Diseases 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
102000003792 Metallothionein Human genes 0.000 description 1
108090000157 Metallothionein Proteins 0.000 description 1
241000237852 Mollusca Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
241000699660 Mus musculus Species 0.000 description 1
101100400378 Mus musculus Marveld2 gene Proteins 0.000 description 1
FFDGPVCHZBVARC-UHFFFAOYSA-N N,N-dimethylglycine Chemical compound CN(C)CC(O)=O FFDGPVCHZBVARC-UHFFFAOYSA-N 0.000 description 1
GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 1
OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 1
MBLBDJOUHNCFQT-LXGUWJNJSA-N N-acetylglucosamine Natural products CC(=O)N[C@@H](C=O)[C@@H](O)[C@H](O)[C@H](O)CO MBLBDJOUHNCFQT-LXGUWJNJSA-N 0.000 description 1
241001504519 Papio ursinus Species 0.000 description 1
102100029251 Phagocytosis-stimulating peptide Human genes 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
206010035664 Pneumonia Diseases 0.000 description 1
241000711902 Pneumovirus Species 0.000 description 1
241000288906 Primates Species 0.000 description 1
230000006819 RNA synthesis Effects 0.000 description 1
230000004570 RNA-binding Effects 0.000 description 1
208000035415 Reinfection Diseases 0.000 description 1
206010061603 Respiratory syncytial virus infection Diseases 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102000007562 Serum Albumin Human genes 0.000 description 1
108010071390 Serum Albumin Proteins 0.000 description 1
241000607768 Shigella Species 0.000 description 1
241000144290 Sigmodon hispidus Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
230000024932 T cell mediated immunity Effects 0.000 description 1
230000005867 T cell response Effects 0.000 description 1
108020005038 Terminator Codon Proteins 0.000 description 1
102000006601 Thymidine Kinase Human genes 0.000 description 1
241001664469 Tibicina haematodes Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
239000007983 Tris buffer Substances 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
108010084754 Tuftsin Proteins 0.000 description 1
108010003533 Viral Envelope Proteins Proteins 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
ILRRQNADMUWWFW-UHFFFAOYSA-K aluminium phosphate Chemical compound O1[Al]2OP1(=O)O2 ILRRQNADMUWWFW-UHFFFAOYSA-K 0.000 description 1
125000000539 amino acid group Chemical group 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000002155 anti-virotic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 1
238000000376 autoradiography Methods 0.000 description 1
235000015278 beef Nutrition 0.000 description 1
SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000005540 biological transmission Effects 0.000 description 1
230000001851 biosynthetic effect Effects 0.000 description 1
238000009534 blood test Methods 0.000 description 1
WLZRMCYVCSSEQC-UHFFFAOYSA-N cadmium(2+) Chemical compound [Cd+2] WLZRMCYVCSSEQC-UHFFFAOYSA-N 0.000 description 1
239000001110 calcium chloride Substances 0.000 description 1
235000011148 calcium chloride Nutrition 0.000 description 1
229910001628 calcium chloride Inorganic materials 0.000 description 1
239000000969 carrier Substances 0.000 description 1
239000006143 cell culture medium Substances 0.000 description 1
210000000170 cell membrane Anatomy 0.000 description 1
239000013553 cell monolayer Substances 0.000 description 1
108091092328 cellular RNA Proteins 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000007969 cellular immunity Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
WORJEOGGNQDSOE-UHFFFAOYSA-N chloroform;methanol Chemical compound OC.ClC(Cl)Cl WORJEOGGNQDSOE-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
229910052804 chromium Inorganic materials 0.000 description 1
239000013599 cloning vector Substances 0.000 description 1
238000004440 column chromatography Methods 0.000 description 1
230000009073 conformational modification Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000004132 cross linking Methods 0.000 description 1
239000003431 cross linking reagent Substances 0.000 description 1
210000004748 cultured cell Anatomy 0.000 description 1
235000018417 cysteine Nutrition 0.000 description 1
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
210000000805 cytoplasm Anatomy 0.000 description 1
230000007850 degeneration Effects 0.000 description 1
229940009976 deoxycholate Drugs 0.000 description 1
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000001627 detrimental effect Effects 0.000 description 1
229960000633 dextran sulfate Drugs 0.000 description 1
238000002405 diagnostic procedure Methods 0.000 description 1
ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
230000029087 digestion Effects 0.000 description 1
108700003601 dimethylglycine Proteins 0.000 description 1
230000006806 disease prevention Effects 0.000 description 1
230000009429 distress Effects 0.000 description 1
210000003162 effector t lymphocyte Anatomy 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000007824 enzymatic assay Methods 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
239000004744 fabric Substances 0.000 description 1
230000001605 fetal effect Effects 0.000 description 1
210000002950 fibroblast Anatomy 0.000 description 1
239000012847 fine chemical Substances 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000004817 gas chromatography Methods 0.000 description 1
238000001030 gas--liquid chromatography Methods 0.000 description 1
238000001502 gel electrophoresis Methods 0.000 description 1
238000007429 general method Methods 0.000 description 1
238000010353 genetic engineering Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
230000013595 glycosylation Effects 0.000 description 1
238000006206 glycosylation reaction Methods 0.000 description 1
239000004519 grease Substances 0.000 description 1
235000020256 human milk Nutrition 0.000 description 1
210000004251 human milk Anatomy 0.000 description 1
230000004727 humoral immunity Effects 0.000 description 1
238000009396 hybridization Methods 0.000 description 1
230000002209 hydrophobic effect Effects 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000016784 immunoglobulin production Effects 0.000 description 1
238000010324 immunological assay Methods 0.000 description 1
238000001114 immunoprecipitation Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
239000000411 inducer Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
238000009413 insulation Methods 0.000 description 1
230000003993 interaction Effects 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
239000007928 intraperitoneal injection Substances 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
230000021633 leukocyte mediated immunity Effects 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000002502 liposome Substances 0.000 description 1
210000003563 lymphoid tissue Anatomy 0.000 description 1
239000012139 lysis buffer Substances 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000000873 masking effect Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
230000001035 methylating effect Effects 0.000 description 1
NCWQJOGVLLNWEO-UHFFFAOYSA-N methylsilicon Chemical compound [Si]C NCWQJOGVLLNWEO-UHFFFAOYSA-N 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000010369 molecular cloning Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
230000016379 mucosal immune response Effects 0.000 description 1
BSOQXXWZTUDTEL-ZUYCGGNHSA-N muramyl dipeptide Chemical compound OC(=O)CC[C@H](C(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](C)O[C@H]1[C@H](O)[C@@H](CO)O[C@@H](O)[C@@H]1NC(C)=O BSOQXXWZTUDTEL-ZUYCGGNHSA-N 0.000 description 1
230000003387 muscular Effects 0.000 description 1
229950006780 n-acetylglucosamine Drugs 0.000 description 1
ZLDPNFYTUDQDMJ-UHFFFAOYSA-N n-octadecyloctadecan-1-amine;hydrobromide Chemical compound Br.CCCCCCCCCCCCCCCCCCNCCCCCCCCCCCCCCCCCC ZLDPNFYTUDQDMJ-UHFFFAOYSA-N 0.000 description 1
238000010899 nucleation Methods 0.000 description 1
238000011580 nude mouse model Methods 0.000 description 1
-1 octadecyl amino Chemical group 0.000 description 1
239000003921 oil Substances 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
238000012856 packing Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
239000000902 placebo Substances 0.000 description 1
230000007505 plaque formation Effects 0.000 description 1
229920001983 poloxamer Polymers 0.000 description 1
229920002401 polyacrylamide Polymers 0.000 description 1
238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
230000001402 polyadenylating effect Effects 0.000 description 1
229920000768 polyamine Polymers 0.000 description 1
229920000642 polymer Polymers 0.000 description 1
229920005862 polyol Polymers 0.000 description 1
150000003077 polyols Chemical class 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
230000004481 post-translational protein modification Effects 0.000 description 1
230000001323 posttranslational effect Effects 0.000 description 1
230000003334 potential effect Effects 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
230000009145 protein modification Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
210000003456 pulmonary alveoli Anatomy 0.000 description 1
238000003127 radioimmunoassay Methods 0.000 description 1
238000011552 rat model Methods 0.000 description 1
230000002787 reinforcement Effects 0.000 description 1
230000003362 replicative effect Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
231100000279 safety data Toxicity 0.000 description 1
239000012898 sample dilution Substances 0.000 description 1
230000028327 secretion Effects 0.000 description 1
238000009589 serological test Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
230000003381 solubilizing effect Effects 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
210000004989 spleen cell Anatomy 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
230000010473 stable expression Effects 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000014621 translational initiation Effects 0.000 description 1
230000001296 transplacental effect Effects 0.000 description 1
239000006163 transport media Substances 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
IESDGNYHXIOKRW-LEOABGAYSA-N tuftsin Chemical compound C[C@@H](O)[C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N1CCC[C@H]1C(=O)N[C@H](CCCNC(N)=N)C(O)=O IESDGNYHXIOKRW-LEOABGAYSA-N 0.000 description 1
229940035670 tuftsin Drugs 0.000 description 1
210000001944 turbinate Anatomy 0.000 description 1
239000012646 vaccine adjuvant Substances 0.000 description 1
229940124931 vaccine adjuvant Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
239000013603 viral vector Substances 0.000 description 1
238000012800 visualization Methods 0.000 description 1
230000002747 voluntary effect Effects 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1
239000011701 zinc Substances 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
- C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Virology (AREA)
Genetics & Genomics (AREA)
Molecular Biology (AREA)
General Health & Medical Sciences (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Physics & Mathematics (AREA)
Bioinformatics & Cheminformatics (AREA)
Biotechnology (AREA)
Analytical Chemistry (AREA)
Microbiology (AREA)
Gastroenterology & Hepatology (AREA)
Medicinal Chemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK199000791A 1987-09-29 1990-03-28 Sammensætning til beskyttelse af et dyr eller et menneske mod en infektion fremkaldt af et respiratorisk syncytialt virus samt underenhedsvaccineformulering DK175500B1 (da)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date	Title
US10218087A	1987-09-29	1987-09-29
US10218087		1987-09-29
US24701788		1988-09-20
US07/247,017 US5223254A (en)	1987-09-29	1988-09-20	Respiratory syncytial virus: vaccines
PCT/US1988/003399 WO1989002935A1 (fr)	1987-09-29	1988-09-29	Virus syncytial respiratoire: vaccins et dosages de diagnostic
US8803399		1988-09-29

Publications (3)

Publication Number	Publication Date
DK79190D0 DK79190D0 (da)	1990-03-28
DK79190A DK79190A (da)	1990-05-07
DK175500B1 true DK175500B1 (da)	2004-11-15

Family

ID=26799096

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK199000791A DK175500B1 (da)	1987-09-29	1990-03-28	Sammensætning til beskyttelse af et dyr eller et menneske mod en infektion fremkaldt af et respiratorisk syncytialt virus samt underenhedsvaccineformulering

Country Status (10)

Country	Link
US (1)	US5223254A (fr)
EP (2)	EP0390799B1 (fr)
JP (1)	JP3288692B2 (fr)
KR (1)	KR960013578B1 (fr)
AT (2)	ATE163682T1 (fr)
AU (1)	AU636838B2 (fr)
BR (1)	BR1101088A (fr)
DE (2)	DE3856586T2 (fr)
DK (1)	DK175500B1 (fr)
WO (1)	WO1989002935A1 (fr)

Families Citing this family (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
NZ224422A (en) *	1987-05-05	1990-11-27	Molecular Eng Ass	Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid
US5223254A (en) *	1987-09-29	1993-06-29	Praxis Biologics, Inc.	Respiratory syncytial virus: vaccines
MX9203458A (es) *	1987-12-23	1992-09-01	Upjohn Co	Segmentos inmunogenicos que contienen glicoproteinas quimericas de las glicoproteinas de virus sincitial respiratorio humano.
EP0540645A4 (en) *	1990-07-24	1993-12-29	The Uab Research Foundation	Methods of use of bovine respiratory syncytial virus recombinant dna, proteins vaccines, antibodies, and transformed cells
US6730305B1 (en)	2000-05-08	2004-05-04	The Uab Research Foundation	Nucleotide sequences encoding bovine respiratory syncytial virus immunogenic proteins
DK0545951T3 (da) *	1990-08-31	1994-10-17	Upjohn Co	HRSV-vaccine
US5824307A (en) *	1991-12-23	1998-10-20	Medimmune, Inc.	Human-murine chimeric antibodies against respiratory syncytial virus
TW275632B (fr) *	1992-04-21	1996-05-11	American Cyanamid Co
US6479055B1 (en)	1993-06-07	2002-11-12	Trimeris, Inc.	Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US6518013B1 (en)	1993-06-07	2003-02-11	Trimeris, Inc.	Methods for the inhibition of epstein-barr virus transmission employing anti-viral peptides capable of abrogating viral fusion and transmission
US6017536A (en) *	1993-06-07	2000-01-25	Trimeris, Inc.	Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
US5464933A (en) *	1993-06-07	1995-11-07	Duke University	Synthetic peptide inhibitors of HIV transmission
CA2167835A1 (fr) *	1993-07-30	1995-02-09	Richard A. Weltzin	Anticorps iga monoclonaux agissant contre le virus respiratoire syncytial
RU2142817C1 (ru) *	1993-08-06	1999-12-20	Коннот Лабораториз Лимитед	Инактивированные вакцины респираторно-синцитиального вируса
US7223410B1 (en)	1994-08-05	2007-05-29	Sanofi Pasteur Limited	Inactivated respiratory syncytial viral vaccines
US5716821A (en) *	1994-09-30	1998-02-10	Uab Research Foundation	Prevention and treatment of respiratory tract disease
US5789229A (en) *	1994-09-30	1998-08-04	Uab Research Foundation	Stranded RNA virus particles
DK0784486T3 (da) *	1994-10-05	2006-08-14	Univ Vanderbilt	Interleukin-12 som en adjuvans til Paramyxoviridae-vacciner
FR2726577B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Procede d'obtention d'un peptide derive du virus respiratoire syncitial, polypeptide et bacterie l'exprimant, et leurs applications a titre de medicament
FR2726576B1 (fr) *	1994-11-07	1997-01-31	Pf Medicament	Production de peptides analogues de peptides hydrophobes, peptide recombinant, sequence d'adn correspondante
US5811524A (en) *	1995-06-07	1998-09-22	Idec Pharmaceuticals Corporation	Neutralizing high affinity human monoclonal antibodies specific to RSV F-protein and methods for their manufacture and therapeutic use thereof
SE9600646D0 (sv) *	1996-02-21	1996-02-21	Bror Morein	Vaccin
US6077514A (en) *	1996-04-04	2000-06-20	The Regents Of The University Of Michigan	Attenuated respiratory syncytial virus
WO1997038138A1 (fr) *	1996-04-04	1997-10-16	The Regents Of The University Of Michigan	Virus respiratoire syncytial attenue
US6180398B1 (en) *	1996-07-12	2001-01-30	Virogeneitics Corporation	Two-step immunization procedure against the pyramyxoviridae family of viruses using recombinant virus and subunit protein preparation
FR2766192B1 (fr) *	1997-07-17	2001-07-13	Pf Medicament	Epitopes du vrs et anticorps les comportant, utiles dans le diagnostic et la therapie
NZ515322A (en) *	1999-05-13	2004-03-26	Wyeth Corp	Adjuvant combination formulations
EP2289550A3 (fr) *	2000-01-27	2012-02-15	MedImmune, LLC	Anticorps à neutralisation d'ultra haute affinité
DK1259547T3 (da)	2000-03-01	2012-10-15	Medimmune Inc	Højpotente, rekombinante antistoffer og fremgangsmåde til fremstilling heraf
US7640062B2 (en)	2000-05-08	2009-12-29	Brainsgate Ltd.	Methods and systems for management of alzheimer's disease
JP4311904B2 (ja)	2000-05-08	2009-08-12	ブレインスゲートリミテッド	血液脳関門及び脳血流の性質を改善するための翼口蓋神経節の刺激方法及び装置
US7117033B2 (en) *	2000-05-08	2006-10-03	Brainsgate, Ltd.	Stimulation for acute conditions
US7146209B2 (en) *	2000-05-08	2006-12-05	Brainsgate, Ltd.	Stimulation for treating eye pathologies
IL155690A0 (en) *	2000-11-10	2003-11-23	Wyeth Corp	Adjuvant combination formulations
US6855493B2 (en)	2000-11-28	2005-02-15	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
US7179900B2 (en) *	2000-11-28	2007-02-20	Medimmune, Inc.	Methods of administering/dosing anti-RSV antibodies for prophylaxis and treatment
FR2827605B1 (fr) *	2001-07-20	2004-07-16	Pf Medicament	Nouveaux peptides derives de la proteine g du vrs et leur utilisation dans un vaccin
US7684859B2 (en) *	2002-04-25	2010-03-23	Brainsgate Ltd.	Stimulation of the OTIC ganglion for treating medical conditions
WO2004043218A2 (fr) *	2002-11-14	2004-05-27	Brainsgate Ltd.	Outils chirurgicaux et techniques de stimulation
AU2003223087A1 (en) *	2002-04-25	2003-11-10	Brainsgate Ltd.	Methods and apparatus for modifying properties of the bbb and cerebral circulation by using the neuroexcitatory and/or neuroinhibitory effects of odorants on nerves in the head
US7132100B2 (en)	2002-06-14	2006-11-07	Medimmune, Inc.	Stabilized liquid anti-RSV antibody formulations
US7561919B2 (en) *	2002-11-14	2009-07-14	Brainsgate Ltd.	SPG stimulation via the greater palatine canal
US9233245B2 (en)	2004-02-20	2016-01-12	Brainsgate Ltd.	SPG stimulation
US8010189B2 (en)	2004-02-20	2011-08-30	Brainsgate Ltd.	SPG stimulation for treating complications of subarachnoid hemorrhage
US8055347B2 (en)	2005-08-19	2011-11-08	Brainsgate Ltd.	Stimulation for treating brain events and other conditions
US20090299418A1 (en) *	2004-08-23	2009-12-03	Brainsgate Ltd.	Concurrent bilateral spg modulation
EP1793850A4 (fr) *	2004-09-21	2010-06-30	Medimmune Inc	Anticorps dirigé contre le virus respiratoire syncytial et procédés de production de vaccins associés
WO2006050166A2 (fr) *	2004-10-29	2006-05-11	Medimmune, Inc.	Methodes de prevention et de traitement des infections a rsv et des etats pathologiques associes
US7875426B2 (en) *	2005-02-04	2011-01-25	University Of South Florida	DNA biochip and methods of use
US20090210026A1 (en) *	2006-08-17	2009-08-20	Brainsgate Ltd.	Spg stimulation for enhancing neurogenesis and brain metabolism
EP1997830A1 (fr)	2007-06-01	2008-12-03	AIMM Therapeutics B.V.	Molécules à liaison spécifiques RSV et leur moyen de fabrication
US7860569B2 (en)	2007-10-18	2010-12-28	Brainsgate, Ltd.	Long-term SPG stimulation therapy for prevention of vascular dementia
US8852608B2 (en)	2009-02-02	2014-10-07	Medimmune, Llc	Antibodies against and methods for producing vaccines for respiratory syncytial virus
US8568726B2 (en)	2009-10-06	2013-10-29	Medimmune Limited	RSV specific binding molecule
CN102294027A (zh) *	2011-07-26	2011-12-28	昆明理工大学	一种呼吸道合胞病毒f2蛋白亚单位疫苗及其制备方法
ES2395677B1 (es) *	2011-07-29	2013-12-26	Instituto De Salud Carlos Iii	Proteína F del VRSH en conformación pre-fusión estabilizada y anticuerpos neutralizantes específicos frente a la misma.
KR102435054B1 (ko)	2012-08-01	2022-08-22	버베리안 노딕 에이/에스	재조합 변형된 백시니아 바이러스 앙카라(ankara) (mva) 호흡기 신시티알 바이러스(rsv) 백신
EP2878335B1 (fr)	2013-11-10	2018-01-03	Brainsgate Ltd.	Implant et système d'implantation pour stimulateur neural
US10271907B2 (en)	2015-05-13	2019-04-30	Brainsgate Ltd.	Implant and delivery system for neural stimulator
JP2025172274A (ja) *	2022-10-20	2025-11-26	一般財団法人阪大微生物病研究会	Ｒｓウイルスワクチンとしての利用に好適な組成物

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU605476B2 (en) *	1986-01-14	1991-01-17	University Of North Carolina, The	Vaccines for human respiratory virus
US5223254A (en) *	1987-09-29	1993-06-29	Praxis Biologics, Inc.	Respiratory syncytial virus: vaccines

1988
- 1988-09-20 US US07/247,017 patent/US5223254A/en not_active Expired - Lifetime
- 1988-09-29 AU AU26133/88A patent/AU636838B2/en not_active Ceased
- 1988-09-29 EP EP88909698A patent/EP0390799B1/fr not_active Revoked
- 1988-09-29 JP JP50892588A patent/JP3288692B2/ja not_active Expired - Fee Related
- 1988-09-29 AT AT88909698T patent/ATE163682T1/de not_active IP Right Cessation
- 1988-09-29 WO PCT/US1988/003399 patent/WO1989002935A1/fr not_active Ceased
- 1988-09-29 EP EP97114674A patent/EP0814089B1/fr not_active Expired - Lifetime
- 1988-09-29 KR KR1019890700960A patent/KR960013578B1/ko not_active Expired - Fee Related
- 1988-09-29 DE DE3856586T patent/DE3856586T2/de not_active Expired - Fee Related
- 1988-09-29 AT AT97114674T patent/ATE307827T1/de not_active IP Right Cessation
- 1988-09-29 DE DE3856141T patent/DE3856141T2/de not_active Revoked
1990
- 1990-03-28 DK DK199000791A patent/DK175500B1/da not_active IP Right Cessation
1997
- 1997-05-14 BR BR1101088-6A patent/BR1101088A/pt active IP Right Grant

Also Published As

Publication number	Publication date
AU636838B2 (en)	1993-05-13
DK79190D0 (da)	1990-03-28
BR1101088A (pt)	2002-04-02
JP3288692B2 (ja)	2002-06-04
EP0814089B1 (fr)	2005-10-26
EP0390799A1 (fr)	1990-10-10
DE3856141D1 (en)	1998-04-09
ATE163682T1 (de)	1998-03-15
WO1989002935A1 (fr)	1989-04-06
US5223254A (en)	1993-06-29
DE3856586T2 (de)	2006-05-24
DE3856141T2 (de)	1998-06-25
AU2613388A (en)	1989-04-18
ATE307827T1 (de)	2005-11-15
EP0390799B1 (fr)	1998-03-04
DE3856586D1 (de)	2005-12-01
EP0814089A2 (fr)	1997-12-29
KR890701770A (ko)	1989-12-21
EP0814089A3 (fr)	2003-12-17
JPH03502687A (ja)	1991-06-20
DK79190A (da)	1990-05-07
KR960013578B1 (ko)	1996-10-09
EP0390799A4 (en)	1992-09-02

Legal Events

Date	Code	Title	Description
2008-05-05	PBP	Patent lapsed	Country of ref document: DK

Publication	Publication Date	Title
DK175500B1 (da)	2004-11-15	Sammensætning til beskyttelse af et dyr eller et menneske mod en infektion fremkaldt af et respiratorisk syncytialt virus samt underenhedsvaccineformulering
US5639853A (en)	1997-06-17	Respiratory syncytial virus vaccines
US20250228927A1 (en)	2025-07-17	Recombinant fusion protein derived from hr region of s2 protein of sars-cov-2 and application of recombinant fusion protein
CN113186173A (zh)	2021-07-30	一种基于减毒流感病毒载体的新型冠状病毒肺炎疫苗
US11896658B2 (en)	2024-02-13	RSV vaccines and methods of production and use thereof
US7645455B2 (en)	2010-01-12	Chimeric lyssavirus nucleic acids and polypeptides
WO2022003119A1 (fr)	2022-01-06	Vaccin contre un coronavirus à réaction croisée
US20230144060A1 (en)	2023-05-11	MERS-CoV VACCINE
Karem et al.	1997	Protective immunity against herpes simplex virus (HSV) type 1 following oral administration of recombinant Salmonella typhimurium vaccine strains expressing HSV antigens
EP0498804B1 (fr)	1997-03-05	Procede de preparation d'un vaccin ou d'un agent toxique
ES2269101T3 (es)	2007-04-01	Vacuna virica con delecion en el gen de bhv-1.
US12258372B2 (en)	2025-03-25	Recombinant vaccine against Marek's disease and Newcastle disease
JPWO2002062381A1 (ja)	2004-06-03	バキュロウイルスベクターワクチン
EP1171454B1 (fr)	2006-05-31	Acides nucleiques et polypeptides de lyssavirus chimeres
Yoo et al.	1997	Maternal immunization of pregnant cattle with recombinant VP8* protein of bovine rotavirus elicits neutralizing antibodies to multiple serotypes: colostral neutralizing antibody by rotavirus VP8
US7238672B1 (en)	2007-07-03	Chimeric lyssavirus nucleic acids and polypeptides
CA1336955C (fr)	1995-09-12	Virus respiratoire syncitial: vaccins et essais diagnostiques
CA1340661C (fr)	1999-07-20	Virus syncytial respiratoire: vaccins et essais diagnostics
Abdelwahab	2007	Immunogenicity and protection efficacy of recombinant fowlpox virus expressing turkey coronavirus nucleocapsid or spike protein
EP1721982B1 (fr)	2013-04-10	Acides nucléiques et polypeptides chimères de Lyssavirus
Ahmad	1992	Expression of lymphokine and viral genes by recombinant baculovirus in insect cells and larvae for development of adjuvant proteins, subunit vaccines, and rapid diagnostic kits
MXPA00000636A (en)	2001-11-21	Nucleic acid vaccines encoding g protein of respiratory syncytial virus